

11th April, 2026

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai 400051

NSE SYMBOL: INVICTA

ISIN: INE0XJ501010

Subject: Outcome of the Board Meeting held on 11th April 2026

Dear Sir/Madam,

In continuation of the outcomes of the Board Meetings held on 5th January, 2026 and 25th March, 2026, and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., Saturday, 11th April, 2026, has, inter alia, approved the draft Share Purchase Agreement (“SPA”) and Shareholders’ Agreement (“SHA”) in relation to the proposed acquisition of Vinchurkar Diagnostics Private Limited, incorporating certain modifications in the terms and conditions of the proposed transaction.

Further, we wish to inform that pursuant to the aforesaid approval, the Company will execute the Share Purchase Agreement and Shareholders’ Agreement on 11th April, 2026.

The revised terms and conditions, as approved by the Board, are broadly in line with the earlier disclosures made to the Stock Exchange(s) pursuant to the Board Meetings held on 5th January, 2026 and 25th March, 2026, with certain changes which do not materially alter the overall structure of the transaction.

Further, the details as required under Regulation 30 read with applicable SEBI Circular are provided in Annexure A below.

The meeting of Board of Directors commenced at 10.00 a.m. and concluded at 12.30 p.m.

Thanking you,

You are requested to take the same on record.

Yours Faithfully,

For Invicta Diagnostic Limited

Sanket Vinod Jain

Chairman and Non-Executive Director

DIN: 08299039

Place: Mumbai

Annexure-1

The disclosures required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, read with SEBI Master Circulars dated November 11, 2024 and December 31, 2024, in relation to the acquisition of Vinchurkar Diagnostics Private Limited, were already submitted as part of the outcome of the Board Meeting held on 5th January, 2026 and 25th March, 2026.

However, in the interest of enhanced corporate governance and compliance, the Company is resubmitting the aforesaid disclosure

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc	<p>Name of the Company to be acquired: Vinchurkar Diagnostics Private Limited</p> <p>Date of Incorporation: 12/05/1993</p> <p>Country of incorporation: H. No. 1372/A, Vinchurkar Banglow Behind SBI, Old Agra Road, Nashik, Maharashtra, India, 422002</p> <p>Brief Profile: Vinchurkar Diagnostics Private Limited is a long-standing diagnostic company in Nashik, India, established in 1993, offering various CT, MRI and Diagnostic tests known for its 24/7 service. It is the first Diagnostic centre who Started Pvt CT & Mammography centre in Nasik in June 1995, MRI in 1999, Superconducting MRI in 2004 etc.</p> <p>Turnover for FY 2024-25: Rs. 445.44 Lakhs</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3	Industry to which the entity being incorporated belongs	Diagnostic Services (Healthcare Service in radiology and pathology solutions)
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for incorporation / acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>The company is engaged, <i>inter alia</i>, in the business of Diagnostic Services (Healthcare Service in radiology and pathology solutions)</p> <p>This acquisition will expand the business activities of the company in Nashik city.</p>
5	Brief details of any governmental or regulatory approvals required for the incorporation / acquisition	None / Not Applicable

6	Indicative time period for completion of the acquisition / Incorporation	Upto 9 Months								
7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash								
8	Cost of subscription/price at which the shares are subscribed / acquired	Proposed cash consideration of Rs. 760 Lakhs								
9	Percentage of shareholding/control by the listed entity and/or number of shares allotted	Proposed acquisition of upto 95% shareholding of Vinchurkar Diagnostics Private Limited in two Tranches i.e. 1 st Tranche 51% upto 31 st May, 2026, 2 nd Tranche of Maximum 44% upto 31 st October, 2026 from the date of execution. Total cash consideration of Rs. 760 Lakhs								
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Brief Background and Significant Information:</p> <p>Vinchurkar Diagnostics Private Limited is a long-standing diagnostic company in Nashik, India, established in 1993, offering various CT, MRI and Diagnostic tests known for its 24/7 service. It is the first Diagnostic centre who Started Pvt CT & Mammography centre in Nasik in June 1995, MRI in 1999, Superconducting MRI in 2004 etc.</p> <p>Country: India</p> <table border="1"> <thead> <tr> <th></th> <th>Turnover (Rs. in lakhs)</th> </tr> </thead> <tbody> <tr> <td>2024-25</td> <td>445.44</td> </tr> <tr> <td>2023-24</td> <td>444.53</td> </tr> <tr> <td>2022-23</td> <td>410.90</td> </tr> </tbody> </table>		Turnover (Rs. in lakhs)	2024-25	445.44	2023-24	444.53	2022-23	410.90
	Turnover (Rs. in lakhs)									
2024-25	445.44									
2023-24	444.53									
2022-23	410.90									

For Invicta Diagnostic Limited

Sanket Vinod Jain
 Chairman and Non-Executive Director
 DIN: 08299039
 Place: Mumbai